Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077408087> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2077408087 abstract "Uterine leiomyomata are benign, monoclonal tumors arising from smooth muscle cells, which belong to one of the most common pathologies of the female genital system. Current pharmacotherapies (oral contraceptives, progestins, GnRH analogs) are ineffective or of limited use for long-term treatment. Although there is still much debate regarding their etiology it is very likely that progesterone and progesterone receptor play a key role in their development. Profound importance of progesterone in the female reproductive system has led to discovery of synthetic progesterone receptor ligands, which can poses the activity ranging from pure agonist activity trough mixed agonist/antagonist activity to pure antagonist activity Development of selective progesterone receptor modulators (SPRM) has created new therapeutic options and has great potential in a number of gynecologic indications. So far, ulipristal acetate has been approved for emergency contraception, mifepristone as a progesterone receptor antagonist because of the unique property of this compound for termination of pregnancy Recently the European Commission has authorized ulipristal acetate for the pre-operative treatment of uterine fibroids. Superior efficacy of ulipristal acetate versus placebo, to reduce excessive uterine bleeding and to reduce total fibroid volume prior to surgery was demonstrated. Moreover non-inferior efficacy of ulipristal acetate versus Gonadotropin Releasing Hormone (GnRH)-agonist to reduce excessive uterine bleeding prior to surgery of uterine fibroids has been documented. Ulipristal acetate is also characterized by a superior side-effect profile in comparison to leuprolide acetate in terms of serum estradiol levels and the proportion of patients with moderate-to-severe hot flashes during treatment. Regarding safety profile, except elevation of liver enzymes after telapristone and onapristone treatment, to date no serious untoward effects of other SPRM have been reported. The issue of endometrial effects of these compounds remains to be resolved, although observation that intrinsic agonist activity of SPRM prevents endometrial proliferation may suggest future use of these agents in prevention of endometrial hyperplasia. Other promising applications, including endometriosis, endometrial cancer Cushing's disease, Alzheimer disease or long-term contraception, are currently in development." @default.
- W2077408087 created "2016-06-24" @default.
- W2077408087 creator A5031211508 @default.
- W2077408087 creator A5051469095 @default.
- W2077408087 creator A5077446787 @default.
- W2077408087 date "2013-01-01" @default.
- W2077408087 modified "2023-09-26" @default.
- W2077408087 title "Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology" @default.
- W2077408087 doi "https://doi.org/10.17772/gp/1642" @default.
- W2077408087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24191519" @default.
- W2077408087 hasPublicationYear "2013" @default.
- W2077408087 type Work @default.
- W2077408087 sameAs 2077408087 @default.
- W2077408087 citedByCount "6" @default.
- W2077408087 countsByYear W20774080872014 @default.
- W2077408087 countsByYear W20774080872016 @default.
- W2077408087 countsByYear W20774080872019 @default.
- W2077408087 crossrefType "journal-article" @default.
- W2077408087 hasAuthorship W2077408087A5031211508 @default.
- W2077408087 hasAuthorship W2077408087A5051469095 @default.
- W2077408087 hasAuthorship W2077408087A5077446787 @default.
- W2077408087 hasBestOaLocation W20774080871 @default.
- W2077408087 hasConcept C121608353 @default.
- W2077408087 hasConcept C126322002 @default.
- W2077408087 hasConcept C134018914 @default.
- W2077408087 hasConcept C141071460 @default.
- W2077408087 hasConcept C170493617 @default.
- W2077408087 hasConcept C2777230143 @default.
- W2077408087 hasConcept C2777486506 @default.
- W2077408087 hasConcept C2777795800 @default.
- W2077408087 hasConcept C2778826759 @default.
- W2077408087 hasConcept C2778938600 @default.
- W2077408087 hasConcept C2779076696 @default.
- W2077408087 hasConcept C2779093440 @default.
- W2077408087 hasConcept C2779234561 @default.
- W2077408087 hasConcept C2780566971 @default.
- W2077408087 hasConcept C2908647359 @default.
- W2077408087 hasConcept C29456083 @default.
- W2077408087 hasConcept C2986817661 @default.
- W2077408087 hasConcept C530470458 @default.
- W2077408087 hasConcept C54355233 @default.
- W2077408087 hasConcept C71924100 @default.
- W2077408087 hasConcept C84606932 @default.
- W2077408087 hasConcept C86803240 @default.
- W2077408087 hasConcept C98717036 @default.
- W2077408087 hasConcept C99454951 @default.
- W2077408087 hasConceptScore W2077408087C121608353 @default.
- W2077408087 hasConceptScore W2077408087C126322002 @default.
- W2077408087 hasConceptScore W2077408087C134018914 @default.
- W2077408087 hasConceptScore W2077408087C141071460 @default.
- W2077408087 hasConceptScore W2077408087C170493617 @default.
- W2077408087 hasConceptScore W2077408087C2777230143 @default.
- W2077408087 hasConceptScore W2077408087C2777486506 @default.
- W2077408087 hasConceptScore W2077408087C2777795800 @default.
- W2077408087 hasConceptScore W2077408087C2778826759 @default.
- W2077408087 hasConceptScore W2077408087C2778938600 @default.
- W2077408087 hasConceptScore W2077408087C2779076696 @default.
- W2077408087 hasConceptScore W2077408087C2779093440 @default.
- W2077408087 hasConceptScore W2077408087C2779234561 @default.
- W2077408087 hasConceptScore W2077408087C2780566971 @default.
- W2077408087 hasConceptScore W2077408087C2908647359 @default.
- W2077408087 hasConceptScore W2077408087C29456083 @default.
- W2077408087 hasConceptScore W2077408087C2986817661 @default.
- W2077408087 hasConceptScore W2077408087C530470458 @default.
- W2077408087 hasConceptScore W2077408087C54355233 @default.
- W2077408087 hasConceptScore W2077408087C71924100 @default.
- W2077408087 hasConceptScore W2077408087C84606932 @default.
- W2077408087 hasConceptScore W2077408087C86803240 @default.
- W2077408087 hasConceptScore W2077408087C98717036 @default.
- W2077408087 hasConceptScore W2077408087C99454951 @default.
- W2077408087 hasIssue "9" @default.
- W2077408087 hasLocation W20774080871 @default.
- W2077408087 hasLocation W20774080872 @default.
- W2077408087 hasLocation W20774080873 @default.
- W2077408087 hasOpenAccess W2077408087 @default.
- W2077408087 hasPrimaryLocation W20774080871 @default.
- W2077408087 hasRelatedWork W1627267625 @default.
- W2077408087 hasRelatedWork W2077408087 @default.
- W2077408087 hasRelatedWork W2130426448 @default.
- W2077408087 hasRelatedWork W2171626715 @default.
- W2077408087 hasRelatedWork W2180221738 @default.
- W2077408087 hasRelatedWork W2402981865 @default.
- W2077408087 hasRelatedWork W2774794536 @default.
- W2077408087 hasRelatedWork W2899820374 @default.
- W2077408087 hasRelatedWork W3022558870 @default.
- W2077408087 hasRelatedWork W4205197507 @default.
- W2077408087 hasVolume "84" @default.
- W2077408087 isParatext "false" @default.
- W2077408087 isRetracted "false" @default.
- W2077408087 magId "2077408087" @default.
- W2077408087 workType "article" @default.